Preventing varicella zoster infection in immunocompromised adults with varicella zoster-specific immunoglobulins.

Our findings demonstrate the utility of VZVSIG as PEP in one of the largest cohorts of immunocompromised adults to date. No early varicella infection was found following exposure, supporting the current recommendations of the VZVSIG administration.